Author

Darren Finlay

Sanford Burnham Prebys Medical Discovery InstituteORCID 0000-0002-8718-9453Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

Kristiina VuoriiD· 3 shared Rabi MuradiD· 3 shared Aniruddha J. DeshpandeiD· 2 shared Aditi Pedgaonkar· 1 shared Akshata Udyavar· 1 shared Alexandra Stevens· 1 shared Alice SoragniiD· 1 shared Amy Carr· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Kristiina VuoriORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Disrupting a Convergent Acetylation Circuit Collapses Leukemic Identity Across AML Subtypes

Anagha Deshpande, Cho-Ying Chiang, Marlenne Perales, Neha Niranjan, Neelam Sinha, Darren Finlay, Alexandra Stevens, Emily Zahn, Benjamin A. Garcia, Irmela Jeremias, Mark Wunderlich, Kristen Jensen-Pergakes, Akshata Udyavar, Amy Carr, Andrew R. Nager, , Aniruddha J. Deshpande

This paper identifies an acetylation-dependent circuit controlling SEC integrity in AML, showing that disrupting KAT2A/B leads to broad anti-leukemic effects across subtypes.

bioRxiv · Jul 14, 2026 · PreprintCancer Biology

Unveiling Genomic Rearrangements in Engineered iPSC Lines by Optical Genome Mapping

Darren Finlay, Pooja Hor, Benjamin Goldenson, Xiaohua Li, Rabi Murad, Dan S. Kaufman, Kristiina Vuori

This study uses optical genome mapping to detect genomic rearrangements in gene-edited iPSCs, showing that transposons and lentiviral methods cause more insertions than CRISPR-Cas9.

Molecular Therapy — Methods & Clinical Development · Nov 20, 2025Peer-reviewedMolecular Biology

SUMO2 Inhibition Reverses Aberrant Epigenetic Rewiring Driven by Synovial Sarcoma Fusion Oncoproteins and Impairs Sarcomagenesis

Rema Iyer, Anagha J. Deshpande, Aditi Pedgaonkar, Pramod Akula Bala, Taehee Kim, Gerard L. Brien, Darren Finlay, Kristiina Vuori, Alice Soragni, Hiromi I Wetterstein, Rabi Murad, Aniruddha J. Deshpande

This study identifies SUMO2 as a selective vulnerability in synovial sarcoma, showing that SUMO2 inhibition reverses SS18-SSX-driven gene expression and impairs tumor growth.

The EMBO Journal · Aug 13, 2025Peer-reviewedCancer Biology